COMMITMENTS AND CONTINGENCIES (Details) (USD $)	3 Months Ended								12 Months Ended				12 Months Ended							12 Months Ended														12 Months Ended					21 Months Ended	60 Months Ended	12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013 Access Pharmaceuticals [Member]	Dec. 31, 2013 Access Pharmaceuticals [Member] Annual Sales, Certain Products [Member] Minimum [Member]	Dec. 31, 2013 Access Pharmaceuticals [Member] Annual Sales, Certain Products [Member] Maximum [Member]	Dec. 31, 2013 Access Pharmaceuticals [Member] Annual Sales, Any One Certain Product [Member]	Dec. 31, 2013 Access Pharmaceuticals [Member] Cumulative Sales, Certain Products [Member] Minimum [Member]	Dec. 31, 2013 Access Pharmaceuticals [Member] Cumulative Sales, Certain Products [Member] Maximum [Member]	Mar. 07, 2008 ProStrakan Ltd [Member]	Mar. 07, 2008 ProStrakan Ltd [Member] Maximum [Member]	Dec. 31, 2013 Kerry P. Gray [Member]		Dec. 31, 2012 Kerry P. Gray [Member]		Dec. 31, 2011 Kerry P. Gray [Member]		Dec. 31, 2013 Terrance K. Wallberg [Member]	Dec. 31, 2012 Terrance K. Wallberg [Member]	Dec. 31, 2011 Terrance K. Wallberg [Member]	Dec. 31, 2013 Key Executives [Member]	Dec. 31, 2012 Key Executives [Member]	Dec. 31, 2011 Key Executives [Member]	Dec. 31, 2013 Chairman, CEO and President [Member]	Mar. 09, 2009 Chairman, CEO and President [Member]	Dec. 31, 2013 Accounts Receivable [Member] Customer Concentration Risk [Member]	Dec. 31, 2012 Accounts Receivable [Member] Customer Concentration Risk [Member]	Dec. 31, 2013 Sales Revenue, Net [Member] Customer Concentration Risk [Member]	Dec. 31, 2012 Sales Revenue, Net [Member] Customer Concentration Risk [Member]	Dec. 31, 2013 Office and Laboratory Space [Member]	Dec. 31, 2012 Office and Laboratory Space [Member]	Mar. 31, 2011 Office and Laboratory Space [Member]	Dec. 31, 2013 Office and Laboratory Space [Member] March 31, 2014 [Member]	Dec. 31, 2013 Office Equipment [Member]
Operating Leased Assets [Line Items]
Minimum monthly lease obligation																																						$ 9,193	$ 9,776	$ 9,330	$ 9,379	$ 744
Future minimum lease payments [Abstract]
2014	120,917								120,917
2015	28,881								28,881
2016	0								0
2017	0								0
2018	0								0
Total	149,798								149,798
Rent expense for operating lease									116,488	130,065
Concentration Risk [Line Items]
Revenues	129,060	110,580	28,884	102,044	165,456	88,922	56,211	60,005	370,568	370,594																										281,000	117,000
Accounts receivable, net	185,078				111,898				185,078	111,898																								174,000	101,000
Concentration risk percentage (in hundredths)									67.00%	59.00%																								97.00%	77.00%	76.00%	32.00%
Separation Agreements [Line Items]
Total separation benefit payments																																	400,000
Period for separation benefit payments																																48 months	12 months
Monthly separation benefits payments																																	12,500
Forfeited stock options due to separation (in shares)																																20,000
Period for separation health coverage																																	24 months
Deferred compensation																																221,500
Separation agreement																																11,500
Stipend for being the Chairman of the Executive Committee																																210,000
Repaid deferred compensation																																(312,500)
Required funding																																(300,000)
Summary of compensation earned, compensation paid in cash, and compensation temporarily deferred [Abstract]
Deferred Compensation Liability									(146,739)	272,156	197,838									(91,000)	[1]	220,673	[1]	140,313	[1]	(35,769)	24,230	36,539	(20,000)	27,253	20,986
Compensation - Deferred	323,225				469,994				323,225	469,994										269,986	[1]					25,000			28,239
Compensation Accounts Payable	207,500				310,000				207,500	310,000
Compensation Accrued Liabilities	115,725				159,994				115,725	159,994
Milestone payments [Line Items]
Future milestone obligations												4,750,000							1,400,000
Milestone for payment													$ 20,000,000	$ 40,000,000	$ 20,000,000	$ 50,000,000	$ 100,000,000
Royalty percentage (in hundredths)																		30.00%

[1] During 2013, Mr. Gray temporarily deferred compensation of $221,500 which consisted of $11,500 earned pursuant to a Separation Agreement and $210,000 for his duties as Chairman of the Executive Committee of the Company’s Board of Directors. During 2013, Mr. Gray was also repaid $312,500 of temporarily deferred compensation, of which $300,000 was used by Mr. Gray for funding required pursuant to the March 2013 Offering.